Engraftment Syndrome: Clinical Features and Predictive Factors in Autologous Stem Cell Transplant
- PMID: 30127551
- PMCID: PMC6081308
- DOI: 10.1007/s12288-017-0899-4
Engraftment Syndrome: Clinical Features and Predictive Factors in Autologous Stem Cell Transplant
Abstract
Engraftment Syndrome (ES) maybe observed in patients who undergo autologous stem cell transplant (SCT). To investigate clinical criteria for ES diagnosis and analyse the risk factors for this complication, we reviewed all auto-SCT cases (Lymphoma and Myeloma) performed during the past 9 years at two tertiary care centres. We analysed all patients with a non-infectious fever, developed within 7 days of engraftment (first day of ANC of 500 on two consecutive days) in 178 patients undergoing autologous stem cell transplant. A total of 46/178 (25.8%) patients developed non-infectious fever and one or more clinical signs of ES within 7 days of engraftment. In all, 29 (61%) fulfilled the Maiolino and 12 (26%) the Spitzer criteria. The incidence of engraftment syndrome using the Maiolino criteria in our study was 29 (15%), which compares well with Spanish study (13% using same criteria) and the original Maiolino study (20%). All patients with ES satisfactorily recovered and discharged with a median of 20 days from hospital. There was no significant difference in number of days of hospitalisation and days of antibiotics between the ES and non ES arms. All patients recovered without any morbidity and only 1 (2%) patient required readmission for fungal pneumonitis. 8 (17%) patients required ICU admission due to delay in initiation of steroids. None of the factors including number of chemotherapy cycles, conditioning regime, disease status, CD34 collection, growth factors and day of WBC engraftment except female (p = 0.064) were statistically significant (in univariate or multivariate analysis). Our study shows that engraftment syndrome is common in autologous transplant setting. Maiolino criteria to diagnose ES is more sensitive in our setting. If detected and treated early there is not much morbidity or mortality related to ES.
Keywords: Autologous stem cell transplantation; Engraftment fever; Engraftment syndrome; Non-infectious fever.
Conflict of interest statement
Compliance with Ethical StandardsNo conflict of interest or funding to be declared.All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Similar articles
-
Engraftment Syndrome: A Retrospective Analysis of the Experience at a Tertiary Care Institute.Clin Hematol Int. 2019 May 24;1(2):114-119. doi: 10.2991/chi.d.190504.001. eCollection 2019 Jun. Clin Hematol Int. 2019. PMID: 34595419 Free PMC article.
-
Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center.Bone Marrow Transplant. 2010 Sep;45(9):1417-22. doi: 10.1038/bmt.2009.363. Epub 2010 Jan 11. Bone Marrow Transplant. 2010. PMID: 20062097
-
Evaluating the incidence of engraftment syndrome with different melphalan formulations in adult multiple myeloma and immunoglobulin light chain amyloidosis patients undergoing autologous hematopoietic cell transplantation.J Oncol Pharm Pract. 2022 Mar;28(2):274-281. doi: 10.1177/1078155220987623. Epub 2021 Jan 12. J Oncol Pharm Pract. 2022. PMID: 33435822
-
Engraftment syndrome following Hematopoietic stem cell transplantation: a systematic approach toward diagnosis and management.Med Oncol. 2022 Dec 2;40(1):36. doi: 10.1007/s12032-022-01894-7. Med Oncol. 2022. PMID: 36460884 Free PMC article. Review.
-
Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach.Biol Blood Marrow Transplant. 2015 Dec;21(12):2061-2068. doi: 10.1016/j.bbmt.2015.08.030. Epub 2015 Aug 29. Biol Blood Marrow Transplant. 2015. PMID: 26327628 Free PMC article. Review.
Cited by
-
Engraftment Syndrome in Autologous Hematopoietic Stem Cell Transplant Patients: Incidence, Associated Risk Factors, Features, and Outcomes.Ann Transplant. 2024 Jul 23;29:e944043. doi: 10.12659/AOT.944043. Ann Transplant. 2024. PMID: 39039776 Free PMC article.
-
Successful Treatment of Severe Steroid-Resistant Engraftment Syndrome Following Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia with Emapalumab: A Case Report.Cancer Manag Res. 2024 Jun 4;16:585-591. doi: 10.2147/CMAR.S458577. eCollection 2024. Cancer Manag Res. 2024. PMID: 38855328 Free PMC article.
-
Plerixafor-based mobilization and mononuclear cell counts in graft increased the risk of engraftment syndrome after autologous hematopoietic stem cell transplantation.Blood Sci. 2024 May 16;6(3):e00190. doi: 10.1097/BS9.0000000000000190. eCollection 2024 Jul. Blood Sci. 2024. PMID: 38779304 Free PMC article.
-
[Incidence and clinical characteristics of engraftment syndrome after syngeneic hematopoietic stem cell transplantation in patients with hematological diseases].Zhonghua Xue Ye Xue Za Zhi. 2023 Apr 14;44(4):289-294. doi: 10.3760/cma.j.issn.0253-2727.2023.04.005. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 37356997 Free PMC article. Chinese.
-
What Is Different in Acute Hematologic Malignancy-Associated ARDS? An Overview of the Literature.Medicina (Kaunas). 2022 Sep 3;58(9):1215. doi: 10.3390/medicina58091215. Medicina (Kaunas). 2022. PMID: 36143892 Free PMC article. Review.
References
-
- Lee CK, Gingrich RD, Hohl RJ, et al. Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation. Bone Marrow Transplant. 1995;16:175–182. - PubMed
-
- Rabinowitz J, Petros WP, Stuart AR, et al. Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support. Blood. 1993;81(9):2452–2459. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous